Abstract: Membrane-integral pyrophosphatases (mPPases) are found in several human pathogens, including Plasmodium species, the protozoan parasites that cause malaria. These enzymes hydrolyze pyrophosphate and couple this to the pumping of ions (H + and/or Na + ) across a membrane to generate an electrochemical gradient. mPPases play an important role in stress tolerance in plants, protozoan parasites, and bacteria. The solved structures of mPPases from Vigna radiata and Thermotoga maritima open the possibility of using structure-based drug design to generate novel molecules or repurpose known molecules against this enzyme. Here, we review the current state of knowledge regarding mPPases, focusing on their structure, the proposed mechanism of action, and their role in human pathogens. We also summarize different methodologies in structure-based drug design and propose an example region on the mPPase structure that can be exploited by these structure-based methods for drug targeting. Since mPPases are not found in animals and humans, this enzyme is a promising potential drug target against livestock and human pathogens.
Introduction
Inorganic pyrophosphatases catalyse the hydrolysis of inorganic pyrophosphate (PP i ) to two inorganic phosphate (P i ) molecules. PP i is a by-product of at least 190 cellular reactions, including the generation of the fundamental building blocks of life: polynucleotide chain synthesis and generation of aminoacyl-tRNA. Controlling the level of PP i is crucial for driving these reactions forward, thus highlighting the importance of pyrophosphatases (PPases) [1] [2] [3] [4] . PP i also plays a regulatory role in the cell as an intracellular biochemical intermediate of several enzymes and e.g. in mammals as an inhibitor of calcification in connective tissue matrices and other extracellular fluids [2, 5] .
Managing the level of PP i in the cell through PP i hydrolysis is primarily accomplished by the ubiquitous soluble PPases (sPPases), which have k cat ranging from 200 to 2000 s -1 , as opposed to the much slower membrane-bound PPases (mPPases) with k cat of approximately 10 s -1 [2, 6] . Chen et al.
demonstrated that sPPase is essential in Escherichia coli through replacement of the chromosomal copy of ppa, the sPPase gene, with ppa under the control of a lac promoter. This strain grew in the presence of isopropyl β-D-1-thiogalactoside (IPTG), which induced expression of sPPase, but was unable to grow in the absence of IPTG [7] . Mitochondrial sPPase in Saccharomyces cerevisiae is also essential for cell viability, since this enzyme is required for mitochondrial function [8] . E. coli sPPase, and other bacterial sPPases, are homohexamers whereas the S. cerevisiae sPPase is a homodimer, though the monomeric fold of these various proteins is the same [9, 10] . Unlike the globular sPPase, mPPase is embedded in the membrane via 15 to 17 transmembrane helices (TMHs), with no globular domain [11, 12] . In addition to hydrolyzing PP i , mPPases couple this action with the pumping of ions across the membrane to generate an electrochemical gradient [13] . This ion gradient can be utilized as a source of energy by the cell during times of stress [14] . Also unlike the sPPases, mPPases only occur in algae, plants, selected species of protozoan parasites, bacteria and archaea -but not in animals or fungi [13, 15, 16] . Below, we discuss the biology, function and structure of mPPases, and finish by discussing the possibility of using mPPases as a novel drug target.
mPPase Sub-Families
mPPase enzymes are divided into four groups based on their requirement for K + , and the ion or ions that they pump across the membrane (summarized in Table 1 ). The first group consists of mPPases that translocate H + across the membrane in a K + -independent manner [17] . Second, are mPPases that pump H + across the membrane, but require 30 to 50 mM K + for optimal activity [18] .
Dependence on K + for function is due to the presence or absence of a key lysine residue in the active site; in K + -independent mPPases the lysine side chain functionally replaces the K + ion. This was demonstrated with the K + -dependent, H + -pumping mPPase from Carboxydotherums hydrogenoformans: this enzyme was converted to a K + -independent mPPase when the alanine 460 residue, which is at the position of the conserved lysine in K + -independent mPPases, was mutated to lysine [19] . The structural basis is not yet certain, as there are no structures of a K + -independent mPPase, but modeling suggests that it is a direct structural replacement of the K + by the lysine sidechain [11] . [40] . Of these, malaria has the greatest worldwide impact, with the World Health Organization estimating 198 million cases and 584 000 deaths due to malaria in 2013 alone [41] . For the purpose of this review, we will use malaria as the prime example to illustrate the various transitions that occur throughout the protozoan parasite life cycle, though similar transitions occur in the other parasite species as well. Malaria is caused by several Plasmodium species, with Plasmodium falciparum being the most prevalent and virulent, and these unicellular parasites are transmitted between humans by Anopheles mosquito vectors [41, 42] . To date, there are no effective, FDAapproved vaccines against malaria, presumably due to the complexities of malarial immune resistance [43] . Despite repeated exposure, most individuals living in areas where malaria is endemic are not immune to Plasmodium infection, though they appear asymptomatic and therefore remain untreated [43, 44] . This population of individuals thus acts as a reservoir for the malaria parasite. Fighting malaria is further complicated by the emergence of P. falciparum strains, especially in south-east Asia [45] , that are resistant to most of the currently-available drugs. The key to tackling the global malaria problem may lie in exploiting the transition between key stages of the complex life cycle of this host-dependent parasite.
The Plasmodium parasite has three major life cycle stages: the human liver stage, the human blood stage, and the mosquito stage [42, 43] . The human liver stage begins when a female Plasmodium-infected Anopheles mosquito transfers the elongated and motile form of the parasite, the sporozoite, from the saliva into the human dermis while it feeds on human blood. These sporozoite parasites reach the bloodstream and travel to the liver, where they invade hepatocytes and replicate [46, 47] . Inside the hepatocytes, the sporozoites differentiate into merozoites, an asexual form of the parasite, which are released into the bloodstream, thereby beginning the human blood stage [47, 48] . The merozoites, which are the main pathogenic form, then go on to infect erythrocytes, in which they replicate and produce more merozoite cells that are again released into the bloodstream. During the human blood stage, some merozoites also differentiate into male or female gametocytes, the non-pathogenic, sexual form of the parasite. The mosquito stage of the life cycle is initiated when mosquitoes take up the gametocyte form of Plasmodium when they feed on infected human blood. In the mosquito, the gametocytes combine in the midgut and produce new, asexual sporozoites, which replicate and spread to the salivary glands, where the parasitic cells can begin the cycle again when the infected mosquito feeds on and infects another human [42, 43] .
During the parasitic life cycle, the unicellular protozoan cell experiences transitions between environments with different levels of osmotic pressure, from intracellular to extracellular environments and from human to vector host environments. Even within the vector insect gut alone, the osmolarity can vary from 320 to 1000 mosmol/kg, depending on the feeding activities of the insect [49] . To survive the changes in environment, the parasites must quickly adjust their internal osmotic pressure [50] . One major mechanism for dealing with this osmotic stress involves a small organelle known as the acidocalcisome [51] . The acidocalcisome acts as an acidic storage compartment for numerous ions, including Ca 2+ , polyphosphate and PP i [52] [53] [54] [55] . During osmotic stress, parasites are able to rapidly hydrolyze or synthesize polyphosphate to adapt to different osmotic environments and to release the energy stored in the polyphosphate molecule [56] . Polyphosphate chelates Ca 2+ ions, and therefore the acidocalcisome likely plays a role in regulating Ca 2+ levels in the protozoan cell [57] . Maintaining a low pH within the acidocalcisome is crucial for acidocalcisome function, and loss of acidocalcisome acidity leads to a 10 fold decrease in polyphosphate levels in the acidocalcisome, a loss of intracellular pH regulation, and decreased growth rate and final cell density in the protozoan parasite Trypanosoma brucei (the cause of African sleeping sickness) [58] . A high concentration of H + within the acidocalcisome is also important for regulating Ca 2+ levels, since one mechanism of Ca 2+ uptake into the acidocalcisome is the exchange of H + for Ca 2+ by Ca 2+ -ATPase [59] . Fusion of the acidocalcisome with the contractile vacuole complex and translocation of aquaporin, which is a water channel, to the contractile vacuole also plays a significant role in osmoregulation in protozoans. This cyclic-AMP-and microtubuledependent fusion mediates the regulatory volume decrease process in Trypanosoma cruzi under hypo-osmotic stress conditions [60] .
Are mPPases validated drug targets?
Just as in plant vacuoles, there are two types of proton pumps in protozoan acidocalcisomes: H + -ATPases and H + -pumping mPPases [61] [62] [63] . Knocking down H + -pumping mPPase expression in T. brucei prevents acidocalcisome acidification, causes a 90% reduction in polyphosphate, and prevents stabilization of intracellular pH on exposure to external basic pH; thus, H + -ATPase activity alone is not sufficient for acidocalcisome activity and a normal parasite [58] . In T. gondii, knockout mutants of mPPase display a reduction in the virulence of tachyzoites in mice; these are the fastgrowing, asexual form of the parasite [64] . In addition, Rodrigues et al. showed that bisphosphonate derivatives (mPPase inhibitors) were able to significantly inhibit intracellular proliferation of T.
gondii in human foreskin fibroblasts without affecting the host cells [65] . Bisphosphonate derivatives also inhibit the growth of P. falciparum, T. brucei, T. cruzi, and Leishmania donovani with nanomolar or low-micromolar IC 50 values [65] [66] [67] . However the mechanism of action of these bisphosphonates is complex, as they inhibit not only mPPase, but also farnesyl pyrophosphate synthase (FPPS), which occurs in mammalian cells as well [67] . Indeed, bisphosphonates are used to treat bone diseases [68] . Despite the fact that bisphosphonates are used to inhibit human enzymes, a recent study by Yang et al. suggests several lipophilic bisphosphonate molecules have the potential to be used against T. brucei in humans without harmful side effects [39, 69, 70] . Bisphosphonate compounds were screened for cytotoxicity in HEK293T cells and several of these molecules exhibited selectivity indexes (SI) (HEK293T cell 50% cytotoxicity concentration (CC 50 )/50% effective concentration (EC 50 ) against T. brucei) of greater than 50 [39] . Therefore, though most bisphosphonate compounds are not potential candidates as anti-parasitic drugs due to cytotoxicity against human cells, modification of these compounds could lead to decreased cytotoxicity while inhibiting parasitic enzymes.
Together, these studies highlight the importance of PP i -driven proton transport by mPPases in protozoan parasites. They clearly indicate mPPases are viable potential drug targets against human protozoan parasites. By targeting the protozoan mPPase and thus interfering with pH regulation and the ability to adapt to varying osmolarity, protozoan pathogens may no longer survive the transition to different host environments.
mPPases in bacterial pathogens
mPPases are only present in select bacterial species; even within a single genus, some species have an mPPase gene whereas others do not. This is exemplified by the genus Clostridium, in which several species, such as Clostridium leptum and Clostridium botulinum, have Na + /H + mPPases whereas other species, such as Clostridium difficile and Clostridium perfringens, lack mPPase genes entirely [13,21] (Shah, N. R. and Goldman, A. unpublished data). Bacterial species that possess mPPases that are of great importance to human health are B. vulgatus and Bacteroides fragilis, along with several other members of genus Bacteroides [13] . In healthy individuals, Bacteroides form a mutualistic relationship with the human host as part of the intestinal microbiota [71] [72] [73] [74] . However, when these bacteria escape the gut environment, they can cause bacteraemia and abscesses in various places in the human body, including the brain [75] [76] [77] . Bacteroides are the most commonly isolated anaerobic pathogen in humans, and bacteremia caused by Bacteroides species has an associated mortality rate of over 19% [77, 78] . Moreover, they have the highest resistance rates of all anaerobic pathogens, likely due to a wide variety of antibiotic resistance mechanisms [77, 79, 80] , meaning that novel, Bacteroides-specific drugs would be of great use. B. vulgatus has a dual-pumping Na + /H + -mPPase embedded in the inner membrane that hydrolyzes PP i at the cytoplasmic face of the membrane and pumps ions across the inner membrane to the periplasm against a concentration gradient [13]. As in plants, overexpression of mPPase in bacteria leads to greater resistance to stressors, including heat, hydrogen peroxide, and high concentrations of NaCl [81] . Though mPPases are not essential for bacterial survival, inhibiting this enzyme will likely diminish the viability of Bacteroides cells, especially under stressful conditions.
Furthermore, in principle a molecule that could force the mPPase ion gate open, rather than just inhibiting the enzyme, would lead to a leaky inner membrane, collapse the electrochemical gradient driving ATP synthesis, and so cause bacterial cell death. Specifically targeting the mPPase in B. vulgatus would have the added bonus of only affecting bacteria that possess mPPases, thereby limiting disturbance of the gut flora, which can lead to antibiotic-associated diarrhea in 15-25% of antibiotic-treated patients. Colonization of the gut by the microbiota also plays a role in protection against pathogens, so targeting just a fraction of the microbiota could be beneficial [82] . For instance, a significant risk of antibiotic treatment is overgrowth of C. difficile that can lead to recurring C. difficile-induced colitis [83] . Targeting mPPase-containing organisms may not carry the same risk, as much of the microbiota would be preserved [84] .
Structure and Function of mPPases

Overall structure of mPPases
Until now, only the mPPase structure from two species have been solved -one from mung bean (VrPPase) in the inhibitor (imidodiphosphate, IDP) bound state (VrPPase:IDP:Mg 5 ) [12] and one from T. maritima (TmPPase) in the resting (TmPPase:Ca:Mg) and product bound states (TmPPase:P i2 :Mg 4 ) [11]. VrPPase is a proton translocating enzyme and TmPPase is a sodiumtranslocating enzyme. Both structures were solved by X-ray crystallography. The overall structures of both enzymes are very similar (Cα's root mean square deviation (RMSD) 1.57 Å), with complete conservation of the position and identity of all catalytic residues [6]. Both structures consist of a twofold symmetric homodimer in which each monomer has 16 TMHs ( Figure 1A ) [11, 12] . In the TmPPase structure, the dimeric interface is mainly formed via hydrophobic interaction of TMH10, 13, and 15 and some hydrogen bonds [11] as well as an ion pair formed by the C-terminal carboxylate. In VrPPase, in addition to hydrophobic interactions and hydrogen bonds, the dimeric interface contains two salt bridges [12] .
The TMHs of each monomer forms a rose-like arrangement consisting of two rings of helices ( Figure 1B) . The inner ring consists of six TMHs (TMH5-6, TMH11-12, and TMH15-16) and the outer ring consists of the other ten (TMH1-4, TMH7-10, and TMH13-14). Viewed from the cytoplasmic side, both rings are arranged sequentially counterclockwise with the exception of TMH1 [12] . However, the helices in the two rings have opposite tilts (Fig 1B) , such that the inner ring of helices appears to be tilted "clockwise", and the outer ring, except for TMH1, "counterclockwise", viewed from the cytoplasm ( Figure 1B) . Viewed parallel to the membrane (data not shown), this corresponds to the inner ring helices being tilted on average -20° (counterclockwise) from the vertical, and the outer ring helices, except for TMH1, being tilted on average +19° (clockwise). This crossing angle between the helices is thus about 40°, similar to a classic "ridges-ingrooves" arrangement.
TMHs of the inner ring form the active site for the hydrolytic reaction and ion pumping ( Figure  1C ). The inner ring of helices is comprised of four distinct areas: (i) the hydrolytic center, (ii) the coupling funnel, (iii) the gates below the membrane surface, and (iv) the exit channel [11] . The hydrolytic center, about 20 Å above the membrane surface, is a funnel-shaped pocket with highly conserved residues consisting of 12 acidic residues (D below the ionic gate, and is formed by semi-conserved non-polar residues from four TMHs of the inner barrel (TMH5, 6, 12, and 16). This gate likely has the essential function of preventing ion back-flow from the lumen/periplasm to the cytoplasm (6). Below the hydrophobic gate lies the exit channel, which facilitates ion release to the lumen/periplasmic region. Among mPPases, the residues in the exit channel are not conserved, which indicates this region does not play a significant role in the ion release mechanism. 
Hydrolysis and pumping mechanism
Upon substrate binding, the most prominent conformational changes occur in TMH6, 11, and 12 ( Figure 2A ). In the resting state structure of TmPPase, the funnel-shaped pocket is open to the cytoplasmic environment with a pocket volume of 2581 Å 3 ( Figure 2B , left panel). The conserved loop 5-6 cannot be observed in this structure due to a lack of electron density, which is probably due to the flexibility of the loop. Upon substrate binding, the overall TMH structure in the cytoplasmic side constricts via TMH movement toward the center of the binding pocket (Figure 2A-B Figure 2B , middle panel). In this structure, loop 5-6 is clearly ordered (Figure 2A, arrowhead) [86] . After hydrolysis and ion pumping has occurred, the capping of the funnel opens again, as seen in the TmPPase:Pi 2 :Mg 4 structure ( Figure 2B , right panel). In this conformation, the helices are still constricted toward the center of the binding site and there is a further decrease of the pocket volume to 407 Å 3 . However in this structure, loop 5-6 is no longer observed, either due to conformational changes after hydrolysis that cause it to become flexible (to facilitate the pocket opening for phosphate release) or due to the low resolution of the structure (4.0 Å) [11]. Though there are some conformational changes in the TMHs on the cytoplasmic side, the overall TMH conformation on the lumen/periplasmic side of the enzyme is quite rigid. In the structures of both mPPase species, the gate and exit channel are closed, so the exact mechanism of H + or Na + pumping is still not clear [11, 12] . Based on the structure of VrPPase:IDP:Mg 5 , Lin et al.
proposed a "Grotthuss-chain" mechanism to explain the proton translocation process from the cytoplasm to the vacuolar lumen. In this mechanism, the binding of PP i to the funnel-shaped pocket induces the nucleophilic attack of the water molecule, which interacts with D287 54 and other residues in this region on VrPPase results in normal hydrolysis activity but a loss in H + -pumping, which means there is uncoupling between PP i hydrolysis and proton translocation [87] . Based on these data, Kellosalo et al. [11] proposed that PP i binding to the active site induces a larger-scale conformational change than that seen in the static structures. In addition to the closing of the loop between TMH5 and 6, TMH12 would move down further than the 2 Å observed (see above); opening the gate and the exit channel and resulting in the diffusion of an ion to the extracellular medium. This transport increases the overall negative charge in the active site due to loss of the Na + (H + in the proton pumping enzymes) and in particular increase the negative charge on residues D 16.39 and D 6. 43 (the residues that bind the nucleophilic water molecule). This would lead to proton abstraction and catalysis. After hydrolysis, the electrophilic phosphate dissociates from the enzyme, followed by the leaving-group phosphate. This mechanism has the advantage over the "Grotthus-chain" mechanism because it can explain how H + -pumping and Na + -pumping mPPases nonetheless have structurally-conserved active sites [11] .
The importance of mPPase and the availability of structural data give this enzyme great practical interest for structure-based drug design methods to fight various human pathogens.
Structure-Based Drug Design for mPPase
Membrane proteins comprise about 25% of all proteins in the cell and more than 60% of them are drug targets [88, 89] . Among drugs available in the DrugBank database [90] that target human membrane proteins, ~36% target G protein-coupled receptors (GPCRs) and ~8% target ligand-gated ion channels [89] . However, only a small fraction of drugs (~1%) in the database target parasitic organisms [89] . Therefore, since parasitic diseases have worldwide health, social, and economic impacts [40] , new drugs targeting human parasites are urgently needed.
General requirements for drug discovery
For a compound to be a potential drug candidate, there needs to be evidence that it has a disease-modifying action. It is thus clearly important whether the target has been validated or not: as discussed above, mPPases are validated targets, both by RNAi experiments [58] and because of the effect of bisphosphonates [65] [66] [67] . The further research on the effect of small molecules that is nonetheless required would benefit from chemical probes (see below). Another important step is to establish a proof-of-concept that potent mPPase inhibitors would have an effect ex vivo and in animal models. Promising lead compounds targeted at the mPPase can be, for example, further explored using P. falciparum and L. major in ex vivo and mouse models.
A second critical aspect required for a clinical candidate molecule is to achieve a concentrationtime profile in the body that is adequate for the desired efficacy and safety. This is done by optimizing, via synthesis of analogues, the compound profile with respect to its absorption, distribution, metabolism and excretion (ADME) properties. The most common tests are compound permeability (membrane permeation assays such as Caco2 or parallel artificial membrane permeability assay (PAMPA)), solubility and plasma protein binding (which will be determinants in compound bioavailability, and therefore the dose taken; higher doses means higher probability of adverse effects), and metabolic profile (cytochrome P450 (CYP) inhibition). In the case of mPPases, compounds would be orally absorbed and the site of action would be the blood. A favorable ADME profile is usually sought during the early stages of the project when compound libraries are prepared, by avoiding compounds likely to have poor absorption or permeability. The first published and bestknown set of rules for design is Lipinski's "rule of five", meant to avoid poor absorption or permeability: no more than five hydrogen bond donors, no more than ten hydrogen bond acceptors, molecular mass less than 500 Da, and calculated Log P (lipophilicity of the compound) less than 5 [91] .
The third important aspect is toxicity and adverse effects. The commonly tested toxicities are cardiac toxicity (human ether-à-go-go-related gene (hERG) channel inhibition) as well as hepatotoxicity and liver injury; the latter is, in some cases, a consequence of drug-drug interactions at transporters (permeability glycoprotein (P-gp), but also ATP-binding cassette sub-family C member 2 (ABCC2) and multi-antimicrobial extrusion protein (MATE)) and metabolic enzymes such as CYPs. Promiscuous binding, which may lead to adverse effects, is further tested against panels of common targets (GPCRs, kinases). In addition, tests are usually conducted on countertargets, such as phylogenetically related proteins and proteins binding chemically similar ligands. For mPPases, mammals do not contain homologous proteins, making this enzyme a feasible target for drug design. Nonetheless, care should be taken because compounds targeted at phosphate sites are likely to bind promiscuously to other (pyro)phosphate binding proteins -such as FPPS (see above). The compounds developed should be designed to be specific by taking advantage of unique regions and aspects of the binding pocket.
Experimental screening
At the moment only bisphosphonates are known to inhibit the mPPase. The first step to start in any drug development project is to discover novel hit compounds, and in order to do so, a robust assay is needed to complement the virtual screening (below). In our case we have at our disposal an assay to determine the orthophosphate released from the mPPase activity based on the molybdenum blue reaction [92] , which we adapted for high throughput screening (Vidilaseris, K. unpublished).
Hit discovery usually starts with a screening campaign. The libraries may be small to medium size to large size. A current trend in screening is towards miniaturization and automation of screening assays to reduce costs. An important factor is the druggability of the target, i.e. our ability to modulate it with small molecules [93, 94] . In addition, the response towards several analogues is useful to see if trends in the structure-activity relationships may be discerned during screening.
Fragment-based drug discovery has received a lot of attention since the seminal paper of Shuker and coworkers [95] . The strategy is built around assembling small fragments, whose binding is identified by nuclear magnetic resonance (NMR), surface plasmon resonance (SPR), X-ray crystallography (soaking of fragment libraries into crystals), or by other biochemical methods. The crystallographic approaches require crystals that diffract to 2.5 Å or better, which is higherresolution than all except one of the mPPase structures. For GPCRs, another class of membrane proteins, fragment based discovery has proven useful [96] even if NMR screening has required working with protein that is thermostabilized, solubilized and attached to a resin [97] . Such a screening campaign can benefit from the use of computational methods, as described below. One obstacle to the use of such methods is that virtual screening methods need known inhibitors as a control; these do not currently exist for mPPases, as bisphosphonates are so unique they do not work well as a positive control in virtual screening.
Computational screening
Computational approaches have become ever more important in modern drug discovery [98] . In virtual screening, each molecule from a virtual chemical library is docked into the binding pocket and then evaluated by estimating the binding affinity and the fitness within the pocket. Then, the obtained score is used to rank the compounds and select the best hits for experimental testing and biological activity assays. This method can improve the hit rate since only the compounds that are most likely to bind are screened with in vitro assays. It is therefore quicker and cheaper than experimental high throughput screening (HTS) for producing promising binders [99] , and provides a useful first step in an experimental high-throughput pipeline. There are several phases in virtual screening: (i) preparation of the target and database, (ii) docking, scoring, and validation, and (iii) ranking the compounds for experimental testing [99] .
Docking-based virtual screening methods are used to rank libraries based on docking scores. Docking screening usually uses a flexible ligand-rigid protein approach. Decoy compounds are used as controls similar to known active compounds; these can be selected from the Directory of Useful Decoys (DUD) for example [100] . The controls are used to find the optimal parameters to retrieve known compounds with a high rank, better than the inactive decoys. To evaluate the best set of possible solutions from a sampling process, a scoring function is applied. Algorithms commonly used for this purpose include force-field-based scoring functions (calculating the binding energy as the sum of non-bonded interactions between the ligand and the binding site) [101] , empirical functions (breaking down the binding energy into several components, multiplying them by a certain coefficient, and recombining them to produce a final score) [102] , and knowledge-based scoring functions (statistical analysis of solved ligand-protein complex structures) [103] . DOCK [104] , AutoDock [105] , and GOLD [106] use force-field-based scoring functions, LUDI [107] and PLANTS PLP [108] use empirical scoring functions, and SMoG2001 [109] uses knowledge-based scoring functions.
Pharmacophore-based virtual screening methods find compounds that match a set of features with a certain spatial organization. It does not provide a ranking (in its simplest form) but rather a yes/no classification. The features are mapped from existing compounds (shared features) or directly set from the binding site. Pharmacophore modeling usually generates conformations on-the-fly. The control group should possess all the features used to screen the compounds. The screening performance is usually assessed from the ability of the pharmacophore to retrieve known ligands and decoys (true positives and negatives, false positives and negatives); a standard method is to use receiver operating characteristic curves [110] .
An alternative approach, which overcomes the limitations of virtual libraries, is computational de novo design. This can produce unlimited innovation in generating novel small molecule ligands that bind protein targets. Based on initial constraints generated from the input, this method is divided into two strategies: ligand-based (if there is no structure available) and receptor-based [111] . We discuss only the latter. In the receptor-based strategy, the binding site on the target protein is identified and used to generate shape constraints for ligand docking and ligand-receptor interactions (hydrogen bond, electrostatic, and hydrophobic interactions). Methods that can be used to derive interaction sites include rule-based and grid-based methods [111] . The outcome of both is a map of the protein target displaying sites where a ligand might interact favorably. The other method, Multiple Copy Simultaneous Search (MCSS), can determine energetically favorable ligand positions and predict the orientations of the ligand functional groups in the binding site [112] . After randomized positioning of multi-copies of functional groups in the binding pocket, force field minimization is performed and the fragments with the interaction energy below a set threshold are chosen as starting fragments for filtering and further assembly.
For ligand assembly within the binding site, single atoms or fragments can be used as the basic building blocks. The former approach generates more structural variety but increases the number of probable solutions, leads to longer processing times and so makes it more difficult to find suitable candidates. The fragment based-building block method is thus more common nowadays as it reduces the size of the search space significantly, making it faster to find solutions with chemically stable, easy-to-make, drug-like compounds. Further ligand assembly can be performed using e.g. the linking method or the growing method. In the linking method, the fragments are placed in key interaction sites of the binding site and then connected to each other using linkers to create complete molecules. The growing method starts with the placement of a single fragment at a key interaction site of the binding site. The fragment is then grown to introduce proper interactions between the ligand and both the key interaction sites and regions between key interaction sites in the binding site.
LigBuilder [113] and SPROUT [114] are two programs that use both methods for ligand assembly, the latter of which has been used for de novo ligand design to transmembrane regions of membranebound proteins [115] .
Hit expansion and lead optimisation
Once initial hits have been identified by experimental or virtual screening (above), the library must be expanded (hit expansion). This can be done by building focused compound libraries, for example enriched in phosphate bioisosteres. As reviewed elsewhere [116, 117] , such compounds include phosphonates, carboxylates and malonates, sulfamates, squaramides and squaric acids, boron-containing fragments, and phosphorothioates. Hit expansion usually starts with the testing of analogues or compounds sharing similar properties. The binding site structure can be used to guide the synthesis from X-ray crystallography or from docking studies, i.e. structure-based compound design. The most promising compounds are then optimized through an extensive synthesis program, usually investigating the effect of bioiosteric replacement or changes in the main scaffold (scaffold hopping) combined with a battery of tests in vitro and in vivo. Current best practice includes ADME testing [91] as early as possible, as a "mistake" of the field has been a too early strong focus on potency [118] . Hit compounds will be a starting point, but they can also be used as chemical probes to verify the tractability of the target [119] . Chemical probes may also be critical for the development of cheaper or more robust screening assays.
Two examples exemplify the possibilities for discovering inhibitors of the mPPases: FPPS and the deoxycytidine triphosphate pyrophosphatase 1 (dCTPase). FPPS is an important drug target that, like mPPase, binds bisphosphonates. Inhibitors of FPPS have been derived from natural ligands [120] and have been pursued from NMR screening of 400 fragments followed by X-ray crystallography [121] . Another approach for this enzyme used virtual screening of a small library of one thousand compounds followed by two rounds of analogue similarity search of the hits, identifying new classes of FPPS inhibitors, diterpenoids and sesquiterpenoids. This was followed by X-ray crystallography to show that these compounds bind to the isopentenyl diphosphate (IPP) site [122] or to a snapshot conformation found in molecular dynamics simulations [123] . Overall, these studies have identified that FPPS can be inhibited by binding at three different sites: the acidrich catalytic site involved in the binding of three Mg 2+ , the homoallylic site IPP site, a highly positively charged binding pocket and a modulatory site. dCTPase, which regulates the intracellular nucleotide pool through hydrolytic degradation of canonical and noncanonical nucleotide triphosphates (dNTPs), is highly expressed in many cancers. For dCTPase, a collection of 5,500 compounds was screened using a classical high-throughput-adapted Malachite Green assay [124] , a test for the colorimetric detection of inorganic phosphate and the hits optimized using a classical medicinal chemistry approach [125] .
Tractability of the mPPase binding site
The importance of mPPases, the availability of its structure and the fact that mammals do not contain homologous proteins make this enzyme a feasible target for drug design. Though the structure of an mPPase from a pathogenic organism has not yet been solved, structure-based drug design against this group of enzymes is possible using the available solved structure from T. maritima and mung bean, since they have high sequence identity (40 -43% and 44 -53% between mPPases from pathogens P. falciparum, T. gondii, T. brucei, Leishmania mexicana, and B. vulgatus with TmPPase and VrPPase, respectively) with the highest sequence identity in the catalytic regions. Moreover, even though TmPPase and VrPPase translocate different ions and have 42% sequence identity, the active site of both structures are very similar with a root mean square deviation/Cα of 0.84 Å (based on the structure of VrPPase:IDP:Mg 5 and TmPPase:P i2 :Mg 4 ), despite the fact that one is in the resting state and the other has inhibitor bound. This demonstrates the low flexibility of mPPase in the active site, even between different conformations and different species. mPPases from pathogens will also have a similar structure.
Some PPase inhibitors, such as IDP and bisphosphonate derivatives, inhibit mPPase more than sPPases [6, 69] . This is because, even though both sPPase and mPPase hydrolyze PP i , their active site and hydrolytic mechanism are completely different; it is therefore possible to develop drugs that specifically target mPPase but not sPPase. The structural differences and mechanisms of both enzymes were comprehensively explained in Kajander et al. [6] .
The first step in designing drugs against mPPase is identifying ligand-binding sites. The most obvious is the catalytic pocket on the cytoplasmic side of the membrane: competitive inhibitors, like IDP and bisphosphonates, inhibit mPPase activity by competitively binding there, and so these molecules can be used as initial leads for finding other compounds with drug-like properties that specifically target mPPase. Figure 2 ). Inhibition assays of VrPPase show that aminomethylenediphosphonate (AMDP) has a six times greater inhibitory effect on enzyme activity than IDP [126] , but the opposite is true for the sPPase from S. cerevisiae (ScPPase) (53) . Analysis of the ScPPase structures in the resting (pdb code: 1HUJ) and PP i bound states (pdb code: 1E6A) showed that the volume of the pocket is smaller than in mPPase [127] . The greater inhibition of mPPase by AMDP than IDP might be due to the larger pocket size, especially in the resting state structure. Therefore, in order to achieve better fitting and specificity for binding to the hydrolytic pocket of mPPase, de novo design by growing/linking methods can be employed based on the AMDP molecule. The initial hits identified from the structure-based design approaches described above could be further refined using a combination of compound synthesis and screening to increase on-target potency and selectivity against mPPase from human pathogens. The best inhibitor could also be co-crystallized with the mPPase for structure determination to analyze the binding mode of the inhibitor. Developing or identifying new compounds that bind selectively to the active site of mPPases and inhibit activity should lead to novel treatment options against several human pathogens.
Conclusion and Perspectives
A major hurdle for drug discovery against human pathogens is ensuring minimal toxicity towards the host; even antimicrobials that have been approved for use in humans are continuously monitored for evidence of toxicity [128, 129] . An important strategy to minimize the chance of harming human cells is to target biological components that are not present in animals. In this respect, since animals lack an mPPase gene, mPPases are a credible, novel target for drug design against human pathogens that express this enzyme, including several species of protozoan parasites and prokaryotic Bacteroides species. Of the mPPase-expressing human pathogens, malaria, which is caused by protozoan parasites, is arguably the most devastating globally, especially considering that 78% of deaths due to malaria occur in children under the age of 5 [45] .
mPPases play a critical role in stress tolerance and, in protozoa particularly, in adapting to osmotic stress. mPPases appear to be crucial for the various transitions in environment and protozoan cell type that occur over the complex parasitic life cycle. The solved structures of two mPPases, the H + -pumping, K + -dependent V. radiata mPPase and the Na + -pumping T. maritima mPPase, are a good basis for structure-based drug design, either to develop novel molecules or repurpose known molecules against mPPases. In addition to the static structural information gained through crystallographic means, complementary dynamics experiments and modeling can contribute to the drug-discovery process by providing further information regarding conformational changes during the catalytic cycle of the enzyme. However, additional mPPase structures, particularly of a protozoan H + -pumping mPPase and a Na + /H + dual-pumping mPPase, as found in Bacteroides species, would provide valuable information for specifically targeting human pathogens that possess these types of enzymes. Although there are many questions still to be answered in the field, the current state of structural knowledge and the experiments underway in our and other laboratories around the world mean that mPPase is an intriguing candidate for developing precision drugs -ones with a unique target, and so with a reduced chance of side-effects. 
